About VYXEOS

VYXEOS (vix-e-ose) is an intravenous (IV) chemotherapy used for the treatment of adults with certain types of newly-diagnosed acute myeloid leukemia: t-AML or AML-MRC.

Therapy-related AML (t-AML)

AML in people who have previously received chemotherapy or radiation therapy

AML with myelodysplasia-related changes (AML-MRC)

AML in people who have previously had certain types of blood disorders

What is VYXEOS?

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is an intravenous (IV) chemotherapy used for the treatment of adults with certain types of newly-diagnosed acute myeloid leukemia (AML). These types include patients whose AML is related to previously received chemotherapy or radiation therapy (also called therapy-related AML, t-AML) and AML in patients who previously had certain types of blood disorders (also called AML with myelodysplasia-related changes, AML-MRC).

Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.

Important Safety Information